Trial halted: Two-Drug combo tested for tough lung cancers
NCT ID NCT06713798
Summary
This study aimed to see if adding a new drug (tiragolumab) to an existing immunotherapy (atezolizumab) could better control advanced lung cancer in patients with a specific tumor feature. It planned to test this in two groups: patients new to treatment and those whose cancer had progressed on prior immunotherapy. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.